A review of cardiovascular benefits of SGLT2 inhibitors

被引：3
|
作者：
Zhang, Yingxia [1 ]
Han, Qinghua [2 ]
机构：
[1] Shanxi Med Univ, Key Lab Cellular Physiol, Dept Clin Med 1, Minist Educ, Taiyuan, Shanxi, Peoples R China
[2] Shanxi Med Univ, Key Lab Cellular Physiol, Dept Cardiol, Minist Educ,Hosp 1, 85 South Jiefang Rd, Taiyuan 030001, Shanxi, Peoples R China
来源：
MEDICINE | 2022年 / 101卷 / 36期
关键词：
arrhythmia; cardiomyopathy; heart failure; hypertension; mechanism; myocardial infarction; sodium-glucose cotransporter 2 inhibitor; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; EMPAGLIFLOZIN; DAPAGLIFLOZIN; RISK; CARDIOPROTECTION; CANAGLIFLOZIN; ASSOCIATION; DISEASES; DEATH;
D O I：
10.1097/MD.0000000000030310
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Sodium-glucose cotransporter 2 inhibitor (SGLT2I) is a new type of hypoglycemic drug that targets the kidney. As research continues to advance on this topic, it has been found that SGLT2I has multiple protective effects, such as hypoglycemic, cardio-renal protective, antihypertensive, and lipid-lowering effects. This review discusses the current concepts and possible mechanisms of SGLT2I in the treatment of heart failure, myocardial infarction, hypertension, cardiomyopathy and arrhythmia to provide a reference for clinicians to use drugs more reasonably and scientifically.
引用
收藏
页数：5
相关论文
共 50 条
  • [31] SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
    Nikolic, Maja
    Zivkovic, Vladimir
    Jovic, Jovana Joksimovic
    Sretenovic, Jasmina
    Davidovic, Goran
    Simovic, Stefan
    Djokovic, Danijela
    Muric, Nemanja
    Bolevich, Sergey
    Jakovljevic, Vladimir
    [J]. HEART FAILURE REVIEWS, 2022, 27 (03) : 935 - 949
  • [32] Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
    Evans, Marc
    Hicks, Debbie
    Patel, Dipesh
    Patel, Vinod
    McEwan, Phil
    Dashora, Umesh
    [J]. DIABETES THERAPY, 2020, 11 (01) : 37 - 52
  • [33] Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
    Marc Evans
    Debbie Hicks
    Dipesh Patel
    Vinod Patel
    Phil McEwan
    Umesh Dashora
    [J]. Diabetes Therapy, 2020, 11 : 37 - 52
  • [34] SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
    Maja Nikolic
    Vladimir Zivkovic
    Jovana Joksimovic Jovic
    Jasmina Sretenovic
    Goran Davidovic
    Stefan Simovic
    Danijela Djokovic
    Nemanja Muric
    Sergey Bolevich
    Vladimir Jakovljevic
    [J]. Heart Failure Reviews, 2022, 27 : 935 - 949
  • [35] SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms
    Zhang, Yali
    He, Yufeng
    Liu, Siqi
    Deng, Li
    Zuo, Yumei
    Huang, Keming
    Liao, Bin
    Li, Guang
    Feng, Jian
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2023, 23 (06) : 641 - 662
  • [36] SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits
    Elisa Marilly
    Judith Cottin
    Natalia Cabrera
    Catherine Cornu
    Remy Boussageon
    Philippe Moulin
    Jean-Christophe Lega
    François Gueyffier
    Michel Cucherat
    Guillaume Grenet
    [J]. Diabetologia, 2022, 65 : 2000 - 2010
  • [37] SGLT2 inhibitors in diabetes, a systematic review and meta-analysis of cardiovascular outcome trials balancing their benefits against their risks
    Marilly, E.
    Cottin, J.
    Cabrera, N.
    Cornu, C.
    Boussageon, R.
    Moulin, P.
    Lega, J.
    Gueyffier, F.
    Cucherat, M.
    Grenet, G.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S11 - S12
  • [38] SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms
    Yali Zhang
    Yufeng He
    Siqi Liu
    Li Deng
    Yumei Zuo
    Keming Huang
    Bin Liao
    Guang Li
    Jian Feng
    [J]. American Journal of Cardiovascular Drugs, 2023, 23 : 641 - 662
  • [39] SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits
    Marilly, Elisa
    Cottin, Judith
    Cabrera, Natalia
    Cornu, Catherine
    Boussageon, Remy
    Moulin, Philippe
    Lega, Jean-Christophe
    Gueyffier, Francois
    Cucherat, Michel
    Grenet, Guillaume
    [J]. DIABETOLOGIA, 2022, 65 (12) : 2000 - 2010
  • [40] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
    Kalra S.
    [J]. Cardiology and Therapy, 2016, 5 (2) : 161 - 168
12345